Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Account Payables
Amounts the company owes suppliers for goods and services received.
Alumis Inc. Common StockNASDAQ: ALMS
Account Payables · Q2 FY2026 · quarter ended Jun 2026
Account payables falls 14.6% from a year ago
Account payables stood at $12.8M at the end of Q2 FY2026, down 14.6% from a year earlier and up 10.5% from the prior quarter. Over 3 fiscal years it compounded at +80.4% a year.
Context
- Account payables amounted to 2.3% of total assets at the end of Q2 FY2026, down 0.2 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -14.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 10.11M USD
- Year-over-year change
- +5.0%
- 3-year CAGR
- +80.4%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.11M | +5.0% |
| FY2024 | 2024-12-31 | 9.62M | +760.8% |
| FY2023 | 2023-12-31 | 1.12M | -35.0% |
| FY2022 | 2022-12-31 | 1.72M | — |
Account Payables vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -14.6% is the 6th highest of 9, against a peer median of +12.9%.
- Account payables amounts to 2.3% of total assets for ALMS, versus a peer median of 2.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $14.73M USD | +131.8% | +8.3% | 7.4% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $12.8M USD | -14.6% | +80.4% | 2.3% |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €7.58M EUR | — | — | 4.6% |
| Mar 2026 | $7.52M USD | +22.8% | +11.6% | 2.3% | |
| Dec 2025 | $7.17M USD | +28.5% | +13.1% | 62.4% | |
| Mar 2026 | $4.49M USD | +13.5% | -31.6% | 0.9% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $2.29M USD | +12.3% | -31.3% | 2.2% |
| Mar 2026 | €367.06K EUR | -95.6% | +2.7% | 0.8% | |
| Mar 2026 | $356K USD | -47.7% | -63.8% | 0.4% | |
| Mar 2026 | $141.36K USD | -59.2% | +5.8% | 0.2% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | +12.9% | +4.3% | 2.2% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.